A detailed history of Lederer & Associates Investment Counsel transactions in Eli Lilly & CO stock. As of the latest transaction made, Lederer & Associates Investment Counsel holds 305 shares of LLY stock, worth $253,894. This represents 0.19% of its overall portfolio holdings.

Number of Shares
305
Previous 305 -0.0%
Holding current value
$253,894
Previous $276,000 2.17%
% of portfolio
0.19%
Previous 0.2%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$592.2 - $792.28 $180,621 - $241,645
305 New
305 $237,000
Q2 2021

Jul 23, 2021

SELL
$180.55 - $233.54 $55,067 - $71,229
-305 Closed
0 $0
Q1 2021

Apr 19, 2021

BUY
$164.32 - $212.72 $50,117 - $64,879
305 New
305 $56,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $791B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Lederer & Associates Investment Counsel Portfolio

Follow Lederer & Associates Investment Counsel and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lederer & Associates Investment Counsel, based on Form 13F filings with the SEC.

News

Stay updated on Lederer & Associates Investment Counsel with notifications on news.